Clinical Neuroradiology | 2021
Response to Letter to the Editor “Keeping Late Thrombectomy Imaging Protocols Simple to Avoid Analysis Paralysis”
Abstract
Thank you very much for your positive feedback and valuable comments and thoughts on our paper [1]. We do agree that poorer clinical results compared to randomized trials should not frustrate us but rather seize the opportunity to learn from real-world data. DAWN and DEFUSE-3 were necessary to prove the efficacy of endovascular treatment (EVT) in a late time window and opened the treatment to another large group of patients; in order to do so, the most promising patient population had to be selected [2, 3]; however, the low number needed to treat (NNT 2–4) in both the DAWN and DEFUSE3 trials already indicates room for broader selection criteria. We found that the majority of the patients in our multicenter real-world cohort in a late time window did not meet the DAWN/DEFUSE-3 criteria, mainly because computed tomography (CT) perfusion was not performed or may not have been available [4]. Interestingly, the patients in our study who were treated without CT perfusion tended to do better than the patients who were selected by CT perfusion imaging. It is certainly time to question the value of CT perfusion imaging for selecting patients for EVT and our data contribute to this question. CT perfusion may steal valuable time and may also lead to decisions against rather than in favor of treatment [5]. We already learned from ESCAPENA1 that patient selection based on Alberta Stroke Program Early CT Score (ASPECTS) and multiphase CT angiography (mCTA) had similar clinical outcomes when compared with patient selection based on CT perfusion imaging [6].